Difference between revisions of "Team:NUDT CHINA"

 
(42 intermediate revisions by 5 users not shown)
Line 3: Line 3:
  
 
<style>
 
<style>
 +
#mw-content-text p{
 +
    margin: 0px;
 +
}
 
#content {
 
#content {
 
     padding: 0px;
 
     padding: 0px;
Line 79: Line 82:
 
.back-to-top {
 
.back-to-top {
 
   position: fixed;
 
   position: fixed;
   background: #18d26e;
+
   background: #00cccc;
 
   background-repeat: no-repeat;
 
   background-repeat: no-repeat;
 
   background-size: contain;
 
   background-size: contain;
Line 105: Line 108:
 
     bottom: 30px;
 
     bottom: 30px;
 
   }
 
   }
}
 
</style>
 
<style>
 
#twink{
 
font-size:35px;
 
color: green;
 
-webkit-animation: twinkling 3s infinite alternate ease-in-out
 
}
 
.animated{
 
-webkit-animation-duration: 5s;
 
animation-duration: 5s;
 
-webkit-animation-fill-mode: both;
 
animation-fill-mode: both
 
}
 
@-webkit-keyframes twinkling{
 
0%{
 
opacity: 0.5;
 
}
 
100%{
 
opacity: 1;
 
}
 
}
 
@keyframes twinkling{
 
0%{
 
opacity: 0.5;
 
}
 
100%{
 
opacity: 1;
 
}
 
 
}
 
}
 
</style>
 
</style>
  
    <style>
+
<div class="col-md-12" style="background-position: center;height: calc(100vh);;background-size:cover; background-image:url(https://static.igem.org/mediawiki/2018/6/63/T--NUDT_CHINA--Testing_background.jpg);background-repeat:no-repeat;">
.title-h{
+
<p style="font-size:80px;margin: 0 0;padding: 12% 0 5% 8%;color:white;"> </p>
font-size: 10rem;
+
</div>
padding-top: 6%;
+
margin-bottom: 5%;
+
font-weight: normal;
+
letter-spacing: .4rem;
+
/*padding-left: 29.2%;*/
+
-webkit-animation: type 4s steps(50, end) forwards;
+
animation: type 4s steps(50, end) forwards;
+
+
-webkit-text-fill-color: #23527c; 
+
-webkit-text-stroke: 2px #335f87; 
+
background-size: cover;
+
}
+
.typing{
+
color: black;
+
width:100%;
+
white-space:nowrap;
+
overflow:hidden;
+
}
+
@-webkit-keyframes type{
+
from { width: 0;}
+
}
+
 
+
@keyframes type{
+
from { width: 0;}
+
}
+
</style>
+
<script>
+
////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
+
 
+
$(document).ready(function() {
+
 
+
$("#HQ_page").attr('id','');
+
+
 
+
//highlight current page on the menu
+
highlight_current_page_menu();
+
+
//accessing submenus
+
$(".menu_item").click(function(){
+
$(".submenu_control_icon", this).toggleClass("open");
+
$(this).next(".submenu").fadeToggle(400);
+
});
+
+
//mobile menu access
+
$(".igem_2018_team_mobile_bar").click(function(){
+
$(this).next().toggleClass("displaying_menu");
+
});
+
+
});
+
 
+
 
+
function highlight_current_page_menu() {
+
+
var page_url="https://2018.igem.org/";
+
page_url = page_url + wgPageName;
+
$("a[href$='"+ page_url +"']").children().addClass("current_page");
+
+
//if the page is in a submenu, open the submenu and make the appropiate changes
+
if( $( ".current_page" ).hasClass( "submenu_item" )){
+
+
$(".current_page").parent().parent().fadeToggle(400);
+
$(".current_page").parent().parent().prev().addClass("current_page");
+
$(".menu_item.current_page > .submenu_control_icon").toggleClass("open");
+
+
}
+
}
+
 
+
 
+
////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
+
</script>
+
 
+
 
+
<style>
+
/**************************************************************************************************************************************************************************************************/
+
 
+
 
+
 
+
/**************************************************************************************************************************************************************************************************/
+
/* DEFAULT WIKI SETTINGS */
+
/**************************************************************************************************************************************************************************************************/
+
 
+
 
+
#home_logo, #sideMenu { display:none; }
+
#sideMenu, #top_title, .patrollink  {display:none;}
+
#content { margin-left:0px; margin-top:-7px; padding:0px; width:100%;}
+
body {background-color:white; }
+
#bodyContent h1, #bodyContent h2, #bodyContent h3, #bodyContent h4, #bodyContent h5 { margin-bottom: 0px; }
+
 
+
.judges-will-not-evaluate { border: 4px solid #e4dede; padding: 2% !important; width: 92%!important;}
+
 
+
 
+
/**************************************************************************************************************************************************************************************************/
+
/* MENU */
+
/**************************************************************************************************************************************************************************************************/
+
 
+
/*this wraps the whole of the menu*/
+
.igem_2018_team_menu {
+
background-color:#c4baba;
+
border-left: 1px solid #c4baba;
+
display:block;
+
float:right;
+
height:100vh;
+
max-width: 270px;
+
overflow-y: auto;
+
overflow-x: hidden;
+
padding:0px;
+
position:fixed;
+
right:0%;
+
text-align:left;
+
width: 15%;
+
}
+
 
+
 
+
.igem_2018_team_menu.displaying_menu{
+
display:block;
+
}
+
 
+
.igem_2018_team_menu  a {
+
color: #484848;
+
text-decoration:none;
+
}
+
 
+
.igem_2018_team_menu img {
+
width:100%;
+
}
+
 
+
 
+
.igem_2018_team_menu .menu_item {
+
    background-color: #c4baba;
+
    border-bottom: 1px solid #928b8b;
+
    clear: both;
+
color: #484848;
+
    cursor: pointer;
+
float: left;
+
    font-size: 120%;
+
    font-weight: bold;
+
    padding: 15px 0px 15px 5%;
+
  width: 100%;
+
}
+
 
+
.igem_2018_team_menu .menu_item.direct_link {
+
color: #484848;
+
padding-left: 15%;
+
}
+
.igem_2018_team_menu .menu_item:hover {
+
background-color: #ecb656;
+
}
+
 
+
 
+
.igem_2018_team_menu .menu_item .submenu_control_icon {
+
color: #484848;
+
float: left;
+
width: 10%;
+
}
+
 
+
/* submenu icon "+" "-"*/
+
.igem_2018_team_menu .menu_item .submenu_control_icon::before {
+
content: "+";
+
}
+
 
+
/* submenu icon "+"  "-"*/
+
.igem_2018_team_menu .menu_item .submenu_control_icon.open::before {
+
content: "-";
+
}
+
 
+
/*submenu wrapper*/
+
.igem_2018_team_menu .submenu{
+
background-color: #e4dede;
+
clear:both;
+
display:none;
+
float: left; 
+
width:100%;
+
}
+
 
+
/*styling for a submenu item*/
+
.igem_2018_team_menu .submenu .submenu_item {
+
border-bottom: 1px solid #c4baba;
+
  color: #635d5d;
+
    height: 30px;
+
  float: left;
+
    font-size: 110%;
+
font-weight: bold;
+
    padding: 12px 0px 0px 15%;
+
    width: 100%;
+
}
+
 
+
.igem_2018_team_menu .submenu .submenu_item:hover {
+
background-color: #f3bd5d;
+
}
+
 
+
 
+
.igem_2018_team_menu .submenu .submenu_item.current_page,
+
.igem_2018_team_menu .menu_item.current_page,
+
.igem_2018_team_menu .menu_item.direct_link.current_page {
+
background-color:#7acbd8;
+
}
+
 
+
 
+
 
+
/*mobile menu bar styling*/
+
/**************************************************************************************************************************************************************************************************/
+
 
+
 
+
.igem_2018_team_mobile_bar {
+
background-color:#e4dede;
+
border-bottom: 1px solid #c4baba;
+
cursor:pointer;
+
display:none;
+
float:left;
+
margin-top: 0;
+
padding: 5px 0;
+
position:fixed;
+
width:100%;
+
}
+
 
+
.igem_logo_mobile img {
+
width:70px;
+
}
+
 
+
.igem_logo_mobile {
+
float:left;
+
padding-left: 5%;
+
width: 30%;
+
}
+
 
+
.igem_menu_control_mobile img {
+
width:25px;
+
}
+
 
+
.igem_menu_control_mobile {
+
float:right;
+
padding-right:5%;
+
padding-top:5px;
+
text-align:right;
+
width: 30%;
+
}
+
 
+
 
+
 
+
/**************************************************************************************************************************************************************************************************/
+
/* CONTENT OF THE PAGE */
+
/**************************************************************************************************************************************************************************************************/
+
 
+
/* general wrapper for the content */
+
.igem_2018_team_content {
+
background-color:white;
+
display:block;
+
width: 87%;
+
}
+
 
+
/* subwrapper to center content */
+
.igem_2018_team_content .igem_2018_team_column_wrapper {
+
margin:auto;
+
max-width: 1400px;
+
width:90%;
+
}
+
 
+
 
+
 
+
/*general styling*/
+
/**************************************************************************************************************************************************************************************************/
+
 
+
.igem_2018_team_content .igem_2018_team_column_wrapper h1 { font-size: 210%;}
+
.igem_2018_team_content .igem_2018_team_column_wrapper h2 { font-size: 190%;}
+
.igem_2018_team_content .igem_2018_team_column_wrapper h3 { font-size: 170%;}
+
.igem_2018_team_content .igem_2018_team_column_wrapper h4 { font-size: 150%;}
+
.igem_2018_team_content .igem_2018_team_column_wrapper h5 { font-size: 140%;}
+
.igem_2018_team_content .igem_2018_team_column_wrapper h6 { font-size: 130%;}
+
 
+
 
+
/* styling for the titles h1, h2*/
+
.igem_2018_team_content .igem_2018_team_column_wrapper h1, .igem_2018_team_content .igem_2018_team_column_wrapper h2 {
+
border-bottom:0px;
+
color: #635d5d;
+
font-family: "Arial Black", Gadget, sans-serif;
+
padding: 10px 0px;
+
}
+
 
+
/* styling for the titles h3, h3, h5, h6 */
+
.igem_2018_team_content .igem_2018_team_column_wrapper h3,
+
.igem_2018_team_content .igem_2018_team_column_wrapper h4,
+
.igem_2018_team_content .igem_2018_team_column_wrapper h5,
+
.igem_2018_team_content .igem_2018_team_column_wrapper h6 {
+
border-bottom:0px;
+
color: #928b8b; 
+
font-family: "Arial Black", Gadget, sans-serif;
+
padding: 5px 0px;
+
}
+
 
+
/* text */
+
.igem_2018_team_content .igem_2018_team_column_wrapper p {
+
font-size: 130%;
+
font-family: Arial, Helvetica, sans-serif;
+
padding: 5px 0px;
+
text-align: left;
+
color: #484848;
+
}
+
 
+
/* Links */
+
.igem_2018_team_content .igem_2018_team_column_wrapper a {
+
color: #5bc7d8;
+
font-weight: bold;
+
text-decoration: underline;
+
text-decoration-color:#5bc7d8;
+
transition: all 0.4s ease;
+
-webkit-transition: all 0.4s ease;
+
-moz-transition: all 0.4s ease;
+
-ms-transition: all 0.4s ease;
+
-o-transition: all 0.4s ease;
+
}
+
 
+
/* hover for the links */
+
.igem_2018_team_content .igem_2018_team_column_wrapper a:hover {
+
color: #f8b732;
+
text-decoration:none;
+
}
+
 
+
 
+
/* Table */
+
.igem_2018_team_content .igem_2018_team_column_wrapper table {
+
border: 1px solid #928b8b;
+
border-collapse: collapse;
+
font-size: 130%;
+
width: 100%;
+
}
+
 
+
/* table cells */
+
.igem_2018_team_content .igem_2018_team_column_wrapper td {
+
border: 1px solid #c4baba;
+
border-collapse: collapse;
+
font-size: 105%;
+
padding: 10px;
+
vertical-align: text-top;
+
}
+
 
+
/* table headers */
+
.igem_2018_team_content .igem_2018_team_column_wrapper th {
+
background-color:#c4baba;
+
border: 1px solid #928b8b;
+
border-collapse: collapse;
+
font-size: 110%;
+
padding: 10px;
+
vertical-align: text-top;
+
}
+
 
+
 
+
 
+
/* non numbered lists */
+
.igem_2018_team_content .igem_2018_team_column_wrapper ul, .igem_2018_team_content .igem_2018_team_column_wrapper ol {
+
font-size: 130%;
+
font-family: Arial, Helvetica, sans-serif;
+
padding:0px 20px;
+
}
+
 
+
 
+
.igem_2018_team_content .igem_2018_team_column_wrapper ul ul li, .igem_2018_team_content .igem_2018_team_column_wrapper ul ul ul li,
+
.igem_2018_team_content .igem_2018_team_column_wrapper ul ol li, .igem_2018_team_content .igem_2018_team_column_wrapper ul ul ol li,
+
.igem_2018_team_content .igem_2018_team_column_wrapper ol ol li, .igem_2018_team_content .igem_2018_team_column_wrapper ul ol ul li,
+
.igem_2018_team_content .igem_2018_team_column_wrapper ol ul li, .igem_2018_team_content .igem_2018_team_column_wrapper ul ol ol li,
+
.igem_2018_team_content .igem_2018_team_column_wrapper ol ul ul li, .igem_2018_team_content .igem_2018_team_column_wrapper ol ol ul li,
+
.igem_2018_team_content .igem_2018_team_column_wrapper ol ol ol li, .igem_2018_team_content .igem_2018_team_column_wrapper ol ul ol li{ font-size: 76%; }
+
 
+
 
+
 
+
/*layout classes*/
+
/**************************************************************************************************************************************************************************************************/
+
 
+
/*main layout class */
+
.igem_2018_team_content .igem_2018_team_column_wrapper .column  {
+
float:left;
+
margin: 1% 2%;
+
padding: 0px;
+
}
+
 
+
/* 100% */
+
.igem_2018_team_content .igem_2018_team_column_wrapper .column.full_size { width:96%; }
+
 
+
/* 66% */
+
.igem_2018_team_content .igem_2018_team_column_wrapper .column.two_thirds_size { width: 62.6%; }
+
 
+
/* 33% */
+
.igem_2018_team_content .igem_2018_team_column_wrapper .column.third_size { width: 29.3%; }
+
 
+
 
+
 
+
 
+
/*styling for all images*/
+
.igem_2018_team_content .igem_2018_team_column_wrapper .column.full_size img,
+
.igem_2018_team_content .igem_2018_team_column_wrapper .column.two_thirds_size img,
+
.igem_2018_team_content .igem_2018_team_column_wrapper .column.third_size img {
+
margin-bottom: 15px;
+
width: 100%;
+
}
+
 
+
 
+
/* page break */
+
.igem_2018_team_content .igem_2018_team_column_wrapper .clear {
+
clear:both;
+
}
+
/*add extra space to page break with clear class*/
+
.igem_2018_team_content .igem_2018_team_column_wrapper .clear.extra_space {
+
height: 30px;
+
}
+
 
+
/* horizontal line to divide the page*/
+
.igem_2018_team_content .igem_2018_team_column_wrapper .line_divider {
+
    border-top: 1px solid #c4baba;
+
  margin: auto;
+
  width: 98%;
+
}
+
 
+
 
+
 
+
+
/*support classes*/
+
/**************************************************************************************************************************************************************************************************/
+
 
+
 
+
/*Button  */
+
/************************************************/
+
.igem_2018_team_content .igem_2018_team_column_wrapper .button_link {
+
font-size: 130%;
+
margin: 30px auto;
+
text-align: center;
+
}
+
 
+
.igem_2018_team_content .igem_2018_team_column_wrapper .button_link a  {
+
background-color: #5bc7d8;
+
color: #635d5d !important;
+
font-weight: bold;
+
margin: auto;
+
text-decoration: none !important;
+
padding: 10px 15px;
+
}
+
 
+
.igem_2018_team_content .igem_2018_team_column_wrapper .button_link a:hover {
+
background-color: #f8b732 !important; 
+
}
+
 
+
 
+
 
+
.igem_2018_team_content .igem_2018_team_column_wrapper .highlight {
+
padding: 15px 20px;
+
}
+
 
+
.igem_2018_team_content .igem_2018_team_column_wrapper .highlight p,
+
.igem_2018_team_content .igem_2018_team_column_wrapper .highlight h1,
+
.igem_2018_team_content .igem_2018_team_column_wrapper .highlight h2,
+
.igem_2018_team_content .igem_2018_team_column_wrapper .highlight h3,
+
.igem_2018_team_content .igem_2018_team_column_wrapper .highlight h4,
+
.igem_2018_team_content .igem_2018_team_column_wrapper .highlight h5,
+
.igem_2018_team_content .igem_2018_team_column_wrapper .highlight h6 {
+
padding: 5px 15px;
+
}
+
 
+
.igem_2018_team_content .igem_2018_team_column_wrapper .highlight.decoration_background {
+
background-color: #e4dede;
+
}
+
 
+
.igem_2018_team_content .igem_2018_team_column_wrapper .highlight.decoration_A_top {
+
    border-top: 4px solid #5bc7d8;
+
}
+
 
+
 
+
.igem_2018_team_content .igem_2018_team_column_wrapper .highlight.decoration_A_full {
+
    border: 4px solid #5bc7d8;
+
}
+
 
+
.igem_2018_team_content .igem_2018_team_column_wrapper .highlight.decoration_B_top {
+
    border-top: 4px solid #f8b732
+
}
+
 
+
 
+
.igem_2018_team_content .igem_2018_team_column_wrapper .highlight.decoration_B_full {
+
    border: 4px solid #f8b732;
+
}
+
 
+
 
+
 
+
 
+
/*mobile*/
+
/**************************************************************************************************************************************************************************************************/
+
 
+
 
+
/* 1800px  */
+
/************************************************/
+
@media only screen and (max-width: 1800px) {
+
.igem_2018_team_content { width: 85%;}
+
.igem_2018_team_menu {display:block;}
+
}
+
 
+
/* 1400px  */
+
/************************************************/
+
@media only screen and (max-width: 1400px) {
+
.igem_2018_team_menu .menu_item { font-size:100%;}
+
.igem_2018_team_menu .submenu .submenu_item { font-size:90%;}
+
.igem_2018_team_menu {display:block;}
+
}
+
 
+
@media only screen and (max-width: 1001px) {
+
.igem_2018_team_menu {display:block;}
+
}
+
 
+
/* 1000px  */
+
/************************************************/
+
@media only screen and (max-width: 1000px) {
+
.igem_2018_team_content {width:100%; margin-left:0px;}
+
.igem_2018_team_menu {display:none; margin-top: 45px; min-width:50%; width:50%;}
+
.igem_2018_team_mobile_bar {display:block;}
+
.igem_2018_team_content .igem_2018_team_column_wrapper .column.full_size, .igem_2018_team_content .igem_2018_team_column_wrapper .column.two_thirds_size,.igem_2018_team_content .igem_2018_team_column_wrapper .column.third_size {width:96%; }
+
 
+
}
+
 
+
 
+
@media only screen and (max-width: 500px) {
+
.igem_2018_team_menu {min-width:100%; width:100%; }
+
}
+
 
+
 
+
/**************************************************************************************************************************************************************************************************/
+
 
+
 
+
 
+
 
+
 
+
</style>
+
<div class="col-md-12" style="wight:100%;height:700px;background-size:cover; background-image:url(https://static.igem.org/mediawiki/2018/5/58/T--NUDT_CHINA--mainpage-backgroud.png);background-repeat:no-repeat;">
+
<p style="font-size:80px;margin: 0 0;padding: 12% 0 5% 8%;color: black;">Cancer,</p>
+
        <p style="font-size:80px;margin: 0 0;padding: 12% 0 5% 8%;color: black;">No More</p>
+
        <p style="font-size:80px;margin: 0 0;padding: 12% 0 5% 8%;color: black;">Hiding</p>
+
<p style="font-size:41px;margin: 0 0;padding: 0 0 0 8%;color: white;">Designed Protein Degradation Method Based om</p><p style="font-size:41px;margin: 0 0;padding: 0 0 0 8%;color: white;">Trim21 And Nanobody</p></div>
+
  
 
<div class="container">
 
<div class="container">
 
<!-- <div class="col-md-12 column">
 
<p id="twink" style="font-size:35px;">此处是闪烁的内容</p>
 
</div>
 
-->
 
  
 
<div class="col-md-12 column">
 
<div class="col-md-12 column">
Line 688: Line 126:
 
</div>
 
</div>
 
<div class="container">
 
<div class="container">
<div class="col-md-6 column" alt="show_photo" style="background-color:#f3f3f3;margin-top: 4%; ">
+
<div class="col-md-6 column" alt="show_photo" style="background-color:#ffffff;margin-top: 4%;">
           <video style="width:100%;" controls="controls" preload="auto" poster="https://static.igem.org/mediawiki/2018/5/58/T--NUDT_CHINA--mainpage-backgroud.png">
+
           <video style="width:100%;" controls="controls" preload="auto" poster="https://static.igem.org/mediawiki/2018/5/5c/T--NUDT_CHINA--backgroud_video.jpg">
<source src="https://static.igem.org/mediawiki/2016/2/26/T--NUDT_CHINA--OPEN-UP_MOVIE.MOV" type="video/mp4" />
+
<source src="https://static.igem.org/mediawiki/2018/e/ee/T--NUDT_CHINA--video_main_page.mp4" type="video/mp4" />
 
Your browser does not support the video tag. Please click <a href="/wiki/images/2/26/T--NUDT_CHINA--OPEN-UP_MOVIE.MOV">HERE</a> to open this video!
 
Your browser does not support the video tag. Please click <a href="/wiki/images/2/26/T--NUDT_CHINA--OPEN-UP_MOVIE.MOV">HERE</a> to open this video!
 
             </video>
 
             </video>
 
</div>
 
</div>
 
<div class="col-md-6 column">
 
<div class="col-md-6 column">
<p style="font-size:20px;float:left; text-align:justify;">Methods to specifically disrupt protein function have greatly accelerated the systematic researches of protein function and interaction work. There are mainly two approaches utilized to disrupt protein function nowadays: DNA knockout and RNA interference, which act at the genome and mRNA level, respectively.However, these two methods both function slowly and indirectly, giving cells enough time to activate compensatory pathway, this may allow the turnover of target protein and cover protein-related phenotypes. Therefore, a method that directly regulates protein levels is urgently needed. Here, we present a target protein disruption method, which degrade endogenous target proteins acutely in mammalian cells. </p>
+
</br>
 +
</br>
 +
<p style="font-size:24px;float:left; text-align:justify;margin-bottom: 15px;">Interfering with protein expression is a powerful strategy to investigate the function of a protein. TRIM-AWAY, a novel strategy through microinjecting antibody and introducing of Trim21 protein into cells, harnesses the cellular protein degradation machinery to remove unmodified native proteins and allows the study of protein function in diverse cell types. But  its poor cell viability after microinjection or electroporation, the high cost of antibody production, the short lifespan of injected-antibody inside the cell and the technique complexity limit its wide application. </p>
 
</div>
 
</div>
 
<div class="col-md-12 column">
 
<div class="col-md-12 column">
<p style="font-size:20px">hello everyone this is the another example-content part for more imformation. Hello everyone this is the another example-content part for more imformation.Donec id elit non mi porta gravida at eget metus. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Donec sed odio dui. </p>
+
<p style="font-size:24px;margin-bottom: 15px; ">This year through combining TRIM-AWAY strategy and ectopic expression of nanobody, we developed a new method for degrading endogenous proteins in mammalian cells. Basically, parts for expression Trim21 and nanobody-IgG Fc were constructed, and then were inserted in a single vector to realize P2A mediated bicistronic expression. To prove the concept, sequences for GFP nanobody and human IgG Fc fragment expression were ligated for fusion expression. To demonstrate our design, the receptor tyrosine-protein kinase erbB-3 is selected. This protein is able to bind and form the heterodimerization with proteins from the erbB family, which is highly involved in proliferation and metastasis of cancer cells, also implicated in chemotherapeutic resistance through multiple signaling pathways. It has been proved that the downregulation of erbB-3 slows down the process several cancers. In our demonstration, the erbB-3 inhibitory antibody would be expressed along with trim21 in cells and directly functions on erbB-3 to bring down its containment. </p>
<p style="font-size:20px">hello everyone this is the another example-content part for more imformation. Hello everyone this is the another example-content part for more imformation.Donec id elit non mi porta gravida at eget metus. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Donec sed odio dui. </p>
+
 
</div>
 
</div>
 
</div>
 
</div>
 
</html>
 
</html>
 
{{NUDT_CHINA/footer}}
 
{{NUDT_CHINA/footer}}

Latest revision as of 03:20, 18 October 2018

PROJECT DESCRIPTION



Interfering with protein expression is a powerful strategy to investigate the function of a protein. TRIM-AWAY, a novel strategy through microinjecting antibody and introducing of Trim21 protein into cells, harnesses the cellular protein degradation machinery to remove unmodified native proteins and allows the study of protein function in diverse cell types. But its poor cell viability after microinjection or electroporation, the high cost of antibody production, the short lifespan of injected-antibody inside the cell and the technique complexity limit its wide application.

This year through combining TRIM-AWAY strategy and ectopic expression of nanobody, we developed a new method for degrading endogenous proteins in mammalian cells. Basically, parts for expression Trim21 and nanobody-IgG Fc were constructed, and then were inserted in a single vector to realize P2A mediated bicistronic expression. To prove the concept, sequences for GFP nanobody and human IgG Fc fragment expression were ligated for fusion expression. To demonstrate our design, the receptor tyrosine-protein kinase erbB-3 is selected. This protein is able to bind and form the heterodimerization with proteins from the erbB family, which is highly involved in proliferation and metastasis of cancer cells, also implicated in chemotherapeutic resistance through multiple signaling pathways. It has been proved that the downregulation of erbB-3 slows down the process several cancers. In our demonstration, the erbB-3 inhibitory antibody would be expressed along with trim21 in cells and directly functions on erbB-3 to bring down its containment.